Primary plasma cell leukemia in the era of new drugs: Has something changed?

Pellegrino Musto; Livio Pagano; Maria Teresa Petrucci; Fortunato Morabito; Tommaso Caravita; Francesco Di Raimondo; Luca Baldini; Patrizia Tosi; Sara Bringhen; Massimo Offidani; Paola Omede'; Antonino Neri; Fiorella D'Auria; Giovanni Battista Bochicchio; Michele Cavo; Mario Boccadoro; Antonio Palumbo

doi:10.1016/j.critrevonc.2011.04.005

Primary plasma cell leukemia in the era of new drugs: Has something changed?

Pellegrino Musto, Livio Pagano, Maria Teresa Petrucci, Fortunato Morabito, Tommaso Caravita, Francesco Di Raimondo, Luca Baldini, Patrizia Tosi, Sara Bringhen, Massimo Offidani, Paola Omede', Antonino Neri, Fiorella D'Auria, Giovanni Battista Bochicchio, Michele Cavo, Mario Boccadoro, Antonio Palumbo

Risultato della ricerca: Contributo in rivista › Articolo in rivista

15 Citazioni (Scopus)

Abstract

Primary plasma cell leukemia (PPCL) is a rare and aggressive variant of multiple myeloma. This disease is associated with a very poor prognosis, and unfortunately it has not significantly improved during the last three decades. Autologous stem cell transplantation is generally recommended in eligible patients, but survival in transplanted PPCL patients is significantly lower than that of multiple myeloma. Recent preliminary data indicate that new drugs, in particular lenalidomide and bortezomib, could significantly improve the clinical outcome of PPCL, increasing response rate and duration, as well as survival. In this review we report an updated literature analysis about the current therapeutic scenario of PPCL, with a particular focus on the use of novel agents.

Lingua originale	English
pagine (da-a)	141-149
Numero di pagine	9
Rivista	CRITICAL REVIEWS IN ONCOLOGY/HEMATOLOGY
Volume	82
DOI	https://doi.org/10.1016/j.critrevonc.2011.04.005
Stato di pubblicazione	Pubblicato - 2012

Keywords

plasmacell leukemia

Accesso al documento

10.1016/j.critrevonc.2011.04.005

Altri file e collegamenti

Link a IRIS PubliCatt

Cita questo

Musto, P., Pagano, L., Petrucci, M. T., Morabito, F., Caravita, T., Di Raimondo, F., Baldini, L., Tosi, P., Bringhen, S., Offidani, M., Omede', P., Neri, A., D'Auria, F., Bochicchio, G. B., Cavo, M., Boccadoro, M., & Palumbo, A. (2012). Primary plasma cell leukemia in the era of new drugs: Has something changed? CRITICAL REVIEWS IN ONCOLOGY/HEMATOLOGY, 82, 141-149. https://doi.org/10.1016/j.critrevonc.2011.04.005

@article{27114576067b4f0586157bfab548edae,

title = "Primary plasma cell leukemia in the era of new drugs: Has something changed?",

abstract = "Primary plasma cell leukemia (PPCL) is a rare and aggressive variant of multiple myeloma. This disease is associated with a very poor prognosis, and unfortunately it has not significantly improved during the last three decades. Autologous stem cell transplantation is generally recommended in eligible patients, but survival in transplanted PPCL patients is significantly lower than that of multiple myeloma. Recent preliminary data indicate that new drugs, in particular lenalidomide and bortezomib, could significantly improve the clinical outcome of PPCL, increasing response rate and duration, as well as survival. In this review we report an updated literature analysis about the current therapeutic scenario of PPCL, with a particular focus on the use of novel agents.",

keywords = "plasmacell leukemia, plasmacell leukemia",

author = "Pellegrino Musto and Livio Pagano and Petrucci, {Maria Teresa} and Fortunato Morabito and Tommaso Caravita and {Di Raimondo}, Francesco and Luca Baldini and Patrizia Tosi and Sara Bringhen and Massimo Offidani and Paola Omede' and Antonino Neri and Fiorella D'Auria and Bochicchio, {Giovanni Battista} and Michele Cavo and Mario Boccadoro and Antonio Palumbo",

year = "2012",

doi = "10.1016/j.critrevonc.2011.04.005",

language = "English",

volume = "82",

pages = "141--149",

journal = "CRITICAL REVIEWS IN ONCOLOGY/HEMATOLOGY",

issn = "1879-0461",